HER2 Support Group Forums - View Single Post

Lani · 11-03-2006, 08:13 PM

Adjuvant online did not include her2 as one of the variables in providing the
risk percentages. When the man who started it was asked at a conference I attended, I believe his answer was that there were not at that time good enough numbers for the risk reduction with chemo, rads, etc. for her2+ tumors as not enough labs had been testing for her2 (and not accurately enough) to come up with the figures for large numbers.

The risk reduction for chemo+herceptin vs chemo alone are based on 2 No. American trials and HERA and constitute perhaps 500-6000 patients given Herceptin in the adjuvant setting many of which have not been followed for more than 3 or 4 years. There were few node negative patients in the No. American trials and the HERA patients got a wide variety of chemo regimens (more than two dozen I believe). Chemo was given concurrently in a subset of the No. American trials, Herceptin was given following chemo in HERA trials.

It will be difficult to get these numbers for many years, and if Tykerb is
approved soon and begins to be given in the adjuvant setting as well, this will confound the statisticians even more!

Hope I haven't just confused you...it IS confusing...

The point is, it is far from clear!

11-03-2006, 08:13 PM	#8
Lani Senior Member Join Date: Mar 2006 Posts: 4,783	when last I checked (a while ago because I have a MAC and its PC only) Adjuvant online did not include her2 as one of the variables in providing the risk percentages. When the man who started it was asked at a conference I attended, I believe his answer was that there were not at that time good enough numbers for the risk reduction with chemo, rads, etc. for her2+ tumors as not enough labs had been testing for her2 (and not accurately enough) to come up with the figures for large numbers. The risk reduction for chemo+herceptin vs chemo alone are based on 2 No. American trials and HERA and constitute perhaps 500-6000 patients given Herceptin in the adjuvant setting many of which have not been followed for more than 3 or 4 years. There were few node negative patients in the No. American trials and the HERA patients got a wide variety of chemo regimens (more than two dozen I believe). Chemo was given concurrently in a subset of the No. American trials, Herceptin was given following chemo in HERA trials. It will be difficult to get these numbers for many years, and if Tykerb is approved soon and begins to be given in the adjuvant setting as well, this will confound the statisticians even more! Hope I haven't just confused you...it IS confusing... The point is, it is far from clear!